JP2022186861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022186861A5 JP2022186861A5 JP2022170262A JP2022170262A JP2022186861A5 JP 2022186861 A5 JP2022186861 A5 JP 2022186861A5 JP 2022170262 A JP2022170262 A JP 2022170262A JP 2022170262 A JP2022170262 A JP 2022170262A JP 2022186861 A5 JP2022186861 A5 JP 2022186861A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dialysis
- acid
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000502 dialysis Methods 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000003002 pH adjusting agent Substances 0.000 claims 3
- 239000012929 tonicity agent Substances 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- LHEYGVSDVBEYQF-QMMMGPOBSA-N (2s)-2-amino-3-[(3-chloro-2-methyl-5-sulfophenyl)carbamoylamino]propanoic acid Chemical compound CC1=C(Cl)C=C(S(O)(=O)=O)C=C1NC(=O)NC[C@H](N)C(O)=O LHEYGVSDVBEYQF-QMMMGPOBSA-N 0.000 claims 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical group O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019071168 | 2019-04-03 | ||
| JP2019071168 | 2019-04-03 | ||
| JP2020066699A JP7166309B2 (ja) | 2019-04-03 | 2020-04-02 | 安定性の良好な医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020066699A Division JP7166309B2 (ja) | 2019-04-03 | 2020-04-02 | 安定性の良好な医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022186861A JP2022186861A (ja) | 2022-12-15 |
| JP2022186861A5 true JP2022186861A5 (enExample) | 2023-03-23 |
| JP7549633B2 JP7549633B2 (ja) | 2024-09-11 |
Family
ID=72667705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020066699A Active JP7166309B2 (ja) | 2019-04-03 | 2020-04-02 | 安定性の良好な医薬組成物 |
| JP2022170262A Active JP7549633B2 (ja) | 2019-04-03 | 2022-10-25 | 安定性の良好な医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020066699A Active JP7166309B2 (ja) | 2019-04-03 | 2020-04-02 | 安定性の良好な医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220142958A1 (enExample) |
| EP (1) | EP3950058A4 (enExample) |
| JP (2) | JP7166309B2 (enExample) |
| KR (1) | KR20210146280A (enExample) |
| CN (1) | CN113260416A (enExample) |
| BR (1) | BR112021013002A2 (enExample) |
| CA (1) | CA3124687A1 (enExample) |
| WO (1) | WO2020204117A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117247339B (zh) * | 2023-11-16 | 2024-03-12 | 潍坊富邦药业有限公司 | 一种烷基胺衍生物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4154900B1 (en) | 2009-07-29 | 2024-08-28 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| ES2712048T3 (es) * | 2010-03-04 | 2019-05-09 | Ea Pharma Co Ltd | Derivado de alquilamina |
| WO2011108724A1 (ja) * | 2010-03-04 | 2011-09-09 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| JP5423854B2 (ja) | 2011-09-02 | 2014-02-19 | 味の素株式会社 | アルキルアミン誘導体を有効成分とする医薬 |
| WO2014119643A1 (ja) | 2013-01-31 | 2014-08-07 | 千寿製薬株式会社 | 澄明な水性液剤 |
| CN107614486A (zh) * | 2015-06-01 | 2018-01-19 | 味之素株式会社 | 烷基胺衍生物的制造方法及其制造中间体 |
| CN109200024A (zh) * | 2017-07-07 | 2019-01-15 | 江苏恒瑞医药股份有限公司 | 西那卡塞药物组合物及其医药用途 |
| TWI859130B (zh) * | 2017-12-20 | 2024-10-21 | 日商Ｅａ製藥股份有限公司 | 維持透析下之二次性副甲狀腺機能亢進症之預防或治療用醫藥組成物 |
-
2020
- 2020-04-02 JP JP2020066699A patent/JP7166309B2/ja active Active
- 2020-04-02 CA CA3124687A patent/CA3124687A1/en active Pending
- 2020-04-02 CN CN202080007515.8A patent/CN113260416A/zh active Pending
- 2020-04-02 BR BR112021013002-0A patent/BR112021013002A2/pt unknown
- 2020-04-02 EP EP20784332.7A patent/EP3950058A4/en active Pending
- 2020-04-02 US US17/433,121 patent/US20220142958A1/en active Pending
- 2020-04-02 KR KR1020217018868A patent/KR20210146280A/ko not_active Ceased
- 2020-04-02 WO PCT/JP2020/015129 patent/WO2020204117A1/ja not_active Ceased
-
2022
- 2022-10-25 JP JP2022170262A patent/JP7549633B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2372421T3 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos. | |
| ES2259098T3 (es) | Composiciones que comprenden ipatropio y xilometazolina para el tratamiento del resfriado comun. | |
| US20170100392A1 (en) | Treating Sexual Desire Disorders with Flibanserin | |
| KR20120046215A (ko) | 소아를 위한 올로파타딘 비강 스프레이 요법 | |
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| JP2005516904A5 (enExample) | ||
| MXPA06012116A (es) | Uso de flibanserina en el tratamiento del trastornos premestruales y otros trastornos sexuales femeninos. | |
| JP2020523335A5 (enExample) | ||
| JP2006505574A5 (enExample) | ||
| JP2016526554A (ja) | レボセチリジンおよびモンテルカストを含む、改善された安定性を有する複合顆粒製剤 | |
| US20230226017A1 (en) | Methods of treating a coronavirus infection | |
| PH12022552454A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof | |
| CN104013638B (zh) | 当药黄素及其衍生物的用途 | |
| JP2002332229A (ja) | 感冒用組成物 | |
| KR20190009294A (ko) | 비강 울혈을 치료/예방하기 위한 카르복실산 | |
| WO2024139978A1 (zh) | Vofopitant用于治疗肺纤维化的用途 | |
| US7767714B2 (en) | Method of preventing infectious diseases | |
| PT2106258E (pt) | Ibuprofeno contra a tosse | |
| JP2013507443A5 (enExample) | ||
| JP3953031B2 (ja) | 新規感染症予防剤 | |
| US10543187B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| JP2024546513A5 (enExample) | ||
| RU2021123918A (ru) | Лекарственная композиция, обладающая превосходной стабильностью | |
| JPH0761926A (ja) | 点鼻剤 | |
| JP5311825B2 (ja) | ２−イミダゾリン構造を有するα−交感神経興奮薬の新規な使用 |